This article is more than 5 years old. Information may no longer be current.

Visudyne first quarter U.S. revenues down

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, Canada — QLT reported that sales of its age-related macular degeneration drug Visudyne fell 41% in the U.S. in the first quarter of 2006, to $30.5 million. That decline more than overshadowed the increase in sales of 5.3% the drug had outside the United States, the company said in a press release. Total worldwide sales of the drug were $106.8 million during the first quarter, a decrease of 13.7% overall.

Visudyne (verteporfin for injection) sales “were consistent with our internal expectations,” Bob Butchofsky, president and chief executive officer, said in a press release.

Visudyne is co-promoted with Novartis.